At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Randomized, Placebo-Controlled, Single- Center, Dose Optimization Study Evaluating Efficacy and Safety of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults Aged 18-65 Years With a Diagnosis of ADHD
In Brief
A Phase 4 clinical trial evaluating Guanfacine Hydrochloride and Placebo for Adult Attention-Deficit Hyperactivity Disorder. Completed, enrolled 26 participants across 1 site.
Detailed Summary
This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride. The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in adults.
Study Details
Timeline
Interventions
1. mg Guanfacine Hydrochloride (orally) 2. mg Guanfacine Hydrochloride (orally) 3. mg Guanfacine Hydrochloride (orally) 4. mg Guanfacine Hydrochloride (orally) 5. mg Guanfacine Hydrochloride (orally) 6. mg Guanfacine Hydrochloride (orally)
Placebo of matching mg